Related Experiment Video
Updated: May 29, 2026
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma
Jennifer M Atkinson1, Anang A Shelat, Angel Montero Carcaboso
1Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Using a mouse model of ependymoma-a chemoresistant brain tumor-we combined multicell high-throughput screening (HTS), kinome-wide binding assays, and in vivo efficacy studies, to identify potential treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both in vitro and in vivo, e.g., 5-fluorouracil. Our comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.
Insights
Researchers identified new treatments for ependymoma, a chemoresistant brain tumor, by screening drugs for effectiveness against cancer cells while sparing neural stem cells (NSC). This study offers promising therapeutic leads for clinical translation.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Ependymoma is a challenging brain tumor known for its chemoresistance.
- Developing effective treatments that minimize toxicity to normal neural stem cells (NSC) is critical.
Purpose of the Study:
- To identify novel therapeutic strategies for ependymoma.
- To discover treatments with selective toxicity against ependymoma cells compared to normal NSC.
Main Methods:
- Utilized a mouse model of ependymoma.
- Employed multicell high-throughput screening (HTS) and kinome-wide binding assays.
- Conducted in vitro and in vivo efficacy studies.
Main Results:
- Identified kinases in the insulin signaling pathway and centrosome cycle as key regulators of ependymoma proliferation.
- Discovered FDA-approved drugs, such as 5-fluorouracil, exhibiting selective toxicity against ependymoma cells versus NSC.
- Validated findings through in vitro and in vivo experiments.
Conclusions:
- The study provides a comprehensive approach to understanding ependymoma biology and treatment.
- Identified several promising treatment leads for ependymoma with potential for clinical application.
- Highlighted the importance of targeting specific pathways for effective and safe ependymoma therapy.
